RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

  Regeneron's COVID-19 antibody cocktail can now be offered as a preventive measure, the FDA says

If you have been exposed to SARS-CoV-2 and either haven't been vaccinated, or are vaccinated but still at high risk of severe illness, you can now be given the antibody cocktail to prevent infection. The first injection must be administered within 96 hours of exposure.

  Monoclonal antibody treatments could cut COVID-19 hospitalizations significantly — but doctors aren't using their full supply

But getting the drugs to sick patients is challenging. The therapies have to be administered within 10 days of symptoms first appearing, but given testing lags and strains on healthcare services, that window can pass quickly.

  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline.

  Infusion Sites

Before accessing the Infusion Locator tool, we need to know just a little bit about you. This information will help us improve our locator tool to better serve you.

Am I a Candidate For Treatment?

Monoclonal antibody treatments have been authorized by the FDA for patients who have tested positive for COVID-19 in the last ten days, who are 12 years of age and older, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This also includes people who are 65 years of age or older or who have certain chronic medical conditions.

Demand Is Soaring For Antibody Treatment As COVID-19 Cases Surge

Vaccination is the best way to defend yourself against this disease, and everyone should get vaccinated. However, if you get sick, you should get treated, and that's really the role of REGEN-COV and the other monoclonal antibody treatments.

Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients

The world’s largest trial of COVID-19 therapeutics has for the first time produced convincing evidence that a therapy that directly attacks the virus can save hospitalized patients from death. A combination of antibodies called casirivimab and imdevimab, produced by Regeneron, did not lower mortality when all patients in the study were taken together, investigators of the United Kingdom’s Recovery trial announced today—but it reduced deaths by one-fifth among those who did not produce antibodies themselves.

No, the Regeneron drug Trump received is not a Covid-19 “cure”

Why Trump’s promise to bring America a free antibody cocktail to treat Covid-19 is so absurd.

Ronapreve: new COVID-19 treatment has just been authorised – here’s everything you need to know

This therapy is likely to be most beneficial for those with compromised immune systems, such as people with HIV/Aids and cancer, transplant patients on immunosuppressant drugs, and those with immunodeficiency disorders. These people are not only highly susceptible to infections but also respond poorly to vaccination.

Study results strengthen the case for using Regeneron’s antibody cocktail in high-risk Covid patients.

The new results come from a Phase 3 trial that enrolled more than 4,500 patients beginning in late September, around the time virus cases began to climb dangerously in the United States. The study found that patients who got the infused treatment within 10 days of developing symptoms or testing positive had a roughly 70 percent reduced risk of being hospitalized or dying compared with patients who were infused with a placebo.